Kineta, a Seattle-based company developing treatments for viral infections and autoimmune diseases, has raised $942,000 in the form of equity, debt, and options from 25 investors, according to a regulatory filing. The company pulled in a bigger sum in November, garnering about half of a $13 million grant from the National Institutes of Health, in which it will seek to develop new adjuvant compounds that boost the effectiveness of vaccines. “This is evidence that our business model is working,” says Meg O’Connor, Kineta’s director of investor relations.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
